{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:57:30Z","timestamp":1760623050525},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2169\/internalmedicine.56.7956","type":"journal-article","created":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T22:21:04Z","timestamp":1496269264000},"page":"1399-1403","source":"Crossref","is-referenced-by-count":39,"title":["Dermatomyositis with Rapidly Progressive Interstitial Lung Disease Treated with Rituximab: A Report of 3 Cases in Japan"],"prefix":"10.2169","volume":"56","author":[{"given":"Kenichiro","family":"Tokunaga","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Japanese Red Cross Kumamoto Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Hagino","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Teikyo University Chiba Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Kameda H, Nagasawa H, Ogawa H, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute\/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 32: 1719-1726, 2005."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kurita T, Yasuda S, Oba K, et al. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology 54: 39-44, 2015.","DOI":"10.1093\/rheumatology\/keu166"},{"key":"3","unstructured":"3. Labirua A, Lundberg IE. Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol 22: 633-638, 2010."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52: 1571-1576, 2005.","DOI":"10.1002\/art.21023"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Gono T, Kawaguchi Y, Satoh T, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology 49: 1713-1719, 2010.","DOI":"10.1093\/rheumatology\/keq149"},{"key":"6","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/rheumatology\/keq073","volume":"49","author":"T Gono","year":"2010","unstructured":"6. Gono T, Kawaguchi Y, Hara M, et al. Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology 49: 1354-1360, 2010.","journal-title":"Rheumatology","ISSN":"http:\/\/id.crossref.org\/issn\/1460-2172","issn-type":"print"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Marie I, Dominique S, Janvresse A, Levesque H, Menard JF. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med 106: 581-587, 2012.","DOI":"10.1016\/j.rmed.2012.01.001"},{"key":"8","unstructured":"8. Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology 48: 968-971, 2009."},{"key":"9","unstructured":"9. Unger L, Kampf S, L\u00fcthke K, Aringer M. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. Rheumatology 53: 1630-1638, 2014."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Andersson H, Sem M, Lund MB, et al. Long-term experience with rituximab in antisynthetase syndrome-related interstitial lung disease. Rheumatology 54: 1420-1428, 2015.","DOI":"10.1093\/rheumatology\/kev004"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Aggarwal R, Bandos A, Reed AM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheum 66: 740-749, 2014.","DOI":"10.1002\/art.38270"},{"key":"12","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1159\/000346573","volume":"225","author":"A Clottu","year":"2012","unstructured":"12. Clottu A, Laffitte E, Prins C, Chizzolini C. Response of mucocutaneous lesions to rituximab in a case of melanoma differentiation antigen 5-related dermatomyositis. Dermatology 225: 376-380, 2012.","journal-title":"Dermatology","ISSN":"http:\/\/id.crossref.org\/issn\/1018-8665","issn-type":"print"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Watanabe R, Ishii T, Araki K, et al. Successful multi-target therapy using corticosteroid, tacrolimus, cyclophosphamide, and rituximab for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis. Mod Rheumatol 26: 465-466, 2016.","DOI":"10.3109\/14397595.2015.1012797"},{"key":"14","unstructured":"14. Yamaguchi K, Yamaguchi A, Uchida M, et al. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment. Mod Rheumatol 2015 (Epub ahead od print)."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Gono T, Sato S, Kawaguchi Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology 51: 1563-1570, 2012.","DOI":"10.1093\/rheumatology\/kes102"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/11\/56_56.7956\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T03:45:01Z","timestamp":1602215101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/11\/56_56.7956\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.56.7956","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}